

<!-- EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.12.8 -->
<!-- Round: 5 -->
<!-- Creation date: 2011-08-11T23:35:19Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:galt="http://WWW.GALECTINTHERAPEUTICS.COM/20110630" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="galt-20110630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110810_0" unitRef="shares" decimals="INF">74106869</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1110-Q0004_STD_0_20100630_0" unitRef="iso4217_USD" decimals="-3">2863000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">786000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">200000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">376000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">71000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:Assets contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">8160000</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">74000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="shares" decimals="INF">74056869</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AssetsCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">8055000</us-gaap:AssetsCurrent>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">63080000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">3000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">7984000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">63289000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DividendsPayableCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">81000</us-gaap:DividendsPayableCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">8160000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">915000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="shares" decimals="INF">74056869</us-gaap:CommonStockSharesIssued>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">3000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="shares" decimals="INF">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">789000</us-gaap:Liabilities>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">129000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">64000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">38000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <galt:UndesignatedCapitalStockValue contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD" xsi:nil="true" />
  <galt:UndesignatedCapitalStockNoParValue contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</galt:UndesignatedCapitalStockNoParValue>
  <galt:UndesignatedCapitalStockSharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="shares" decimals="INF">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
  <galt:UndesignatedCapitalStockSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0" unitRef="shares" decimals="INF">8001000</galt:UndesignatedCapitalStockSharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x444581" unitRef="shares" decimals="INF">74056869</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="-3">74000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x445724" unitRef="shares" decimals="INF">1562500</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x445724" unitRef="iso4217_USD" decimals="-3">632000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x449416" unitRef="shares" decimals="INF">225</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x449416" unitRef="iso4217_USD" decimals="-3">2203000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">63289000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x478726" unitRef="iso4217_USD" decimals="-3">-63080000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x479231" unitRef="shares" decimals="INF">900000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x479231" unitRef="iso4217_USD" decimals="-3">1673000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x479232" unitRef="shares" decimals="INF">2100000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x479232" unitRef="iso4217_USD" decimals="-3">2580000</us-gaap:StockholdersEquity>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x445724" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x445724" unitRef="shares" decimals="INF">1562500</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x445724" unitRef="shares" decimals="INF">1562500</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x445724" unitRef="iso4217_USD" decimals="-3">632000</us-gaap:PreferredStockValue>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x449416" unitRef="shares" decimals="INF">1000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x449416" unitRef="shares" decimals="INF">225</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityRedemptionValue contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x449416" unitRef="iso4217_USD" decimals="0">4500000</us-gaap:TemporaryEquityRedemptionValue>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x449416" unitRef="shares" decimals="INF">225</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x449416" unitRef="iso4217_USD" decimals="INF">2250000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityCarryingAmount contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x449416" unitRef="iso4217_USD" decimals="-3">2203000</us-gaap:TemporaryEquityCarryingAmount>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479231" unitRef="shares" decimals="INF">900000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479231" unitRef="shares" decimals="INF">900000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityRedemptionValue contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479231" unitRef="iso4217_USD" decimals="0">1800000</us-gaap:TemporaryEquityRedemptionValue>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479231" unitRef="shares" decimals="INF">900000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479231" unitRef="iso4217_USD" decimals="INF">1800000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityCarryingAmount contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479231" unitRef="iso4217_USD" decimals="-3">1673000</us-gaap:TemporaryEquityCarryingAmount>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479232" unitRef="shares" decimals="INF">2100000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479232" unitRef="shares" decimals="INF">2100000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquityRedemptionValue contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479232" unitRef="iso4217_USD" decimals="0">4200000</us-gaap:TemporaryEquityRedemptionValue>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479232" unitRef="shares" decimals="INF">2100000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479232" unitRef="iso4217_USD" decimals="INF">4200000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityCarryingAmount contextRef="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479232" unitRef="iso4217_USD" decimals="-3">2580000</us-gaap:TemporaryEquityCarryingAmount>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1110-Q0004_STD_0_20091231_0" unitRef="iso4217_USD" decimals="-3">251000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1771000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">200000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">537000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">70000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:Assets contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">6300000</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">64000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="shares" decimals="INF">63909155</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AssetsCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">6195000</us-gaap:AssetsCurrent>
  <us-gaap:GrantsReceivableCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">234000</us-gaap:GrantsReceivableCurrent>
  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">56424000</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">12000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">5891000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">54022000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:DividendsPayableCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">48000</us-gaap:DividendsPayableCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">6300000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">861000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">-1694000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="shares" decimals="INF">63909155</us-gaap:CommonStockSharesIssued>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">7000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="shares" decimals="INF">300000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1783000</us-gaap:Liabilities>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">125000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">59000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">39000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <galt:UndesignatedCapitalStockValue contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <galt:UndesignatedCapitalStockNoParValue contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</galt:UndesignatedCapitalStockNoParValue>
  <galt:UndesignatedCapitalStockSharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="shares" decimals="INF">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
  <galt:UndesignatedCapitalStockSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0" unitRef="shares" decimals="INF">8001000</galt:UndesignatedCapitalStockSharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x444581" unitRef="shares" decimals="INF">63909155</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">64000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x445724" unitRef="shares" decimals="INF">1592500</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x445724" unitRef="iso4217_USD" decimals="-3">644000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x449416" unitRef="shares" decimals="INF">212</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x449416" unitRef="iso4217_USD" decimals="-3">2073000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">54022000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x478726" unitRef="iso4217_USD" decimals="-3">-56424000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x479231" unitRef="shares" decimals="INF">900000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x479231" unitRef="iso4217_USD" decimals="-3">1664000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x479232" unitRef="shares" decimals="INF">2100000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x479232" unitRef="iso4217_USD" decimals="-3">2474000</us-gaap:StockholdersEquity>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x445724" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x445724" unitRef="shares" decimals="INF">1592500</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x445724" unitRef="shares" decimals="INF">1592500</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x445724" unitRef="iso4217_USD" decimals="-3">644000</us-gaap:PreferredStockValue>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x449416" unitRef="shares" decimals="INF">1000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x449416" unitRef="shares" decimals="INF">212</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x449416" unitRef="shares" decimals="INF">212</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmount contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x449416" unitRef="iso4217_USD" decimals="-3">2073000</us-gaap:TemporaryEquityCarryingAmount>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x479231" unitRef="shares" decimals="INF">900000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x479231" unitRef="shares" decimals="INF">900000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x479231" unitRef="shares" decimals="INF">900000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmount contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x479231" unitRef="iso4217_USD" decimals="-3">1664000</us-gaap:TemporaryEquityCarryingAmount>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x479232" unitRef="shares" decimals="INF">2100000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x479232" unitRef="shares" decimals="INF">2100000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x479232" unitRef="shares" decimals="INF">2100000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmount contextRef="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x479232" unitRef="iso4217_USD" decimals="-3">2474000</us-gaap:TemporaryEquityCarryingAmount>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-286000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">1000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-1692000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">425000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">1171000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-190000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">1075000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-3792000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-1410000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">363000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-5292000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">8000</us-gaap:DepreciationAndAmortization>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-2382000</us-gaap:OperatingIncomeLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">2612000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">14000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">2382000</us-gaap:OperatingExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">2019000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">4304000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
  <galt:SupplementalDividendsOnConvertiblePreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">425000</galt:SupplementalDividendsOnConvertiblePreferredStock>
  <galt:ProceedsFromExerciseOfStockOptionsAndOtherStockIssuances contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">2841000</galt:ProceedsFromExerciseOfStockOptionsAndOtherStockIssuances>
  <galt:ChangeInFairValueOfWarrant contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-1411000</galt:ChangeInFairValueOfWarrant>
  <galt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="shares" decimals="-3">51916000</galt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <galt:IssuanceOfEquityWarrantsInConnectionWithEquityOfferings contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">1029000</galt:IssuanceOfEquityWarrantsInConnectionWithEquityOfferings>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE87402---1110-Q0004_STD_181_20100630_0_453257x479232" unitRef="iso4217_USD" decimals="-3">1463000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0">GALT</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0">GALECTIN THERAPEUTICS INC</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0">2011-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0">0001133416</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">2039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-9000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-5000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">9000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-2883000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">1022000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">27000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">2039000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-156000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">5000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">234000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">115000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-5519000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-515000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">2035000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-234000</us-gaap:IncreaseDecreaseInOtherReceivables>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-6656000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">5000</us-gaap:DepreciationAndAmortization>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-5004000</us-gaap:OperatingIncomeLoss>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">2093000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">1000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">5004000</us-gaap:OperatingExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">2969000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">4981000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
  <galt:AccretionOfRedeemableConvertiblePreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">88000</galt:AccretionOfRedeemableConvertiblePreferredStock>
  <galt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">6002000</galt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <galt:SupplementalDividendsOnConvertiblePreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">1022000</galt:SupplementalDividendsOnConvertiblePreferredStock>
  <galt:ProceedsFromExerciseOfStockOptionsAndOtherStockIssuances contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">4851000</galt:ProceedsFromExerciseOfStockOptionsAndOtherStockIssuances>
  <galt:ChangeInFairValueOfWarrant contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-524000</galt:ChangeInFairValueOfWarrant>
  <galt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0" unitRef="shares" decimals="-3">68243000</galt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="shares" decimals="INF">913000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="shares" decimals="INF">125000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="shares" decimals="INF">30000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <galt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="-3">8000</galt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <galt:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581" unitRef="shares" decimals="INF">8198794</galt:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <us-gaap:CommonStockDividendsShares contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581_453257x445724" unitRef="shares" decimals="INF">88096</us-gaap:CommonStockDividendsShares>
  <us-gaap:CommonStockDividendsShares contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581_453257x449416" unitRef="shares" decimals="INF">31874</us-gaap:CommonStockDividendsShares>
  <us-gaap:CommonStockDividendsShares contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581_453257x479231" unitRef="shares" decimals="INF">228286</us-gaap:CommonStockDividendsShares>
  <us-gaap:CommonStockDividendsShares contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581_453257x479232" unitRef="shares" decimals="INF">532664</us-gaap:CommonStockDividendsShares>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581_453257x479232" unitRef="iso4217_USD" decimals="-3">-1000</us-gaap:DividendsPreferredStock>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x445724" unitRef="iso4217_USD" decimals="-3">-12000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x445724" unitRef="shares" decimals="INF">-30000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x449416" unitRef="iso4217_USD" decimals="-3">130000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x449416" unitRef="shares" decimals="INF">13</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">2039000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">233000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">12000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <galt:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">5994000</galt:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698_453257x445724" unitRef="iso4217_USD" decimals="-3">-96000</us-gaap:DividendsPreferredStock>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698_453257x449416" unitRef="iso4217_USD" decimals="-3">-34000</us-gaap:DividendsPreferredStock>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698_453257x479231" unitRef="iso4217_USD" decimals="-3">-258000</us-gaap:DividendsPreferredStock>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698_453257x479232" unitRef="iso4217_USD" decimals="-3">-601000</us-gaap:DividendsPreferredStock>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726" unitRef="iso4217_USD" decimals="-3">27000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726" unitRef="iso4217_USD" decimals="-3">-5519000</us-gaap:NetIncomeLoss>
  <galt:AccretionOfRedeemableConvertiblePreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726" unitRef="iso4217_USD" decimals="-3">88000</galt:AccretionOfRedeemableConvertiblePreferredStock>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726_453257x445724" unitRef="iso4217_USD" decimals="-3">95000</us-gaap:DividendsPreferredStock>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726_453257x449416" unitRef="iso4217_USD" decimals="-3">67000</us-gaap:DividendsPreferredStock>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726_453257x479231" unitRef="iso4217_USD" decimals="-3">258000</us-gaap:DividendsPreferredStock>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726_453257x479232" unitRef="iso4217_USD" decimals="-3">602000</us-gaap:DividendsPreferredStock>
  <galt:AccretionOfRedeemableConvertiblePreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x479231" unitRef="iso4217_USD" decimals="-3">-9000</galt:AccretionOfRedeemableConvertiblePreferredStock>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x479232" unitRef="iso4217_USD" decimals="-3">-27000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <galt:AccretionOfRedeemableConvertiblePreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x479232" unitRef="iso4217_USD" decimals="-3">-79000</galt:AccretionOfRedeemableConvertiblePreferredStock>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_453257x445724" unitRef="iso4217_USD" decimals="-3">-1000</us-gaap:DividendsPreferredStock>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_453257x449416" unitRef="iso4217_USD" decimals="-3">130000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:DividendsPreferredStock contextRef="eol_PE87402---1110-Q0004_STD_181_20110630_0_453257x449416" unitRef="iso4217_USD" decimals="-3">33000</us-gaap:DividendsPreferredStock>
  <us-gaap:StockIssued1 contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">107000</us-gaap:StockIssued1>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">9000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Common Stock
Warrants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The following
table summarizes the common stock warrant activity from
December&amp;#xA0;31, 2010 through June&amp;#xA0;30, 2011:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"&gt;
&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="62%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Shares&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;Weighted&amp;#xA0;Average&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;br /&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Exercise
Price&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;
&lt;!-- Begin Table Body --&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Outstanding,
December&amp;#xA0;31, 2010&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;51,515,194&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0.63&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;-&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0.00&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(8,198,794)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0.56&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Forfeited/cancelled&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(527,000)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0.84&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Outstanding, June&amp;#xA0;30,
2011&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;42,789,400&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0.64&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Body --&gt;&lt;/table&gt;
&lt;p style="margin-top:24px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Consultant
Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In April 2009,
the Company entered into agreements with consultants that provided
for the grant of warrants for 330,000 shares of common stock at an
exercise price of $0.50 per share. Of the 330,000 warrants, 200,000
remained unvested as of June&amp;#xA0;30, 2011. The Company valued the
unvested warrants at $167,000 as of June&amp;#xA0;30, 2011 using the
following assumptions: expected life of 1.79 years, volatility of
89%, risk free interest rate of 0.45% and zero dividends. The
Company recognized expense related to the 200,000 warrants of
$12,000 and $20,000 for the three and six months ended
June&amp;#xA0;30, 2011, respectively. The Company recognized expense of
$40,000 and $73,000 for the three and six months ended
June&amp;#xA0;30, 2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In May 2010, the
Company entered into an agreement with a consultant that provided
for the grant of warrants for 72,000 shares of common stock at an
exercise price of $2.50 per share. The warrants vest at a rate of
3,000&amp;#xA0;per month and the unvested warrants will be revalued as
they vest. The following assumptions were used to value the
warrants for the six months ended June&amp;#xA0;30, 2011: an expected
life of 2.99 to 3.32 years, volatility of 128% to 130%, risk free
interest rate of 0.79% to 1.29% and zero dividends. At
June&amp;#xA0;30, 2011, 45,000 warrants were vested and 27,000 were
forfeited upon cancellation of the agreement. The company
recognized an expense of $5,000 and $12,000 related to these
warrants during the three and six months ended June&amp;#xA0;30, 2011,
respectively. The company recognized an expense of $7,000 related
to these warrants during the three and six months ended
June&amp;#xA0;30, 2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In May 2010, the
Company entered into an agreement with a consultant that provided
for the grant of warrants for 500,000 shares of common stock at an
exercise price of $0.75 per share and which vest upon the
achievement of certain milestones. At June&amp;#xA0;30, 2011, all
500,000 warrants were unvested. The Company did not recognize any
expense related to these warrants during the three and six- months
ended June&amp;#xA0;30, 2011 or 2010, as the Company determined that it
was not yet probable that the milestones will be achieved. These
warrants were cancelled during the three months ended June&amp;#xA0;30,
2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In August 2010,
the Company entered into an agreement with a consultant, who was
also a board member, which provided for the grant of warrants for
600,000 shares of common stock at an exercise price of $0.71 per
share. Of the 600,000 warrants, 150,000 vested immediately on
signing of the agreement, 150,000 vest at the end of one year and
the remaining 300,000 warrants were to vest based on the
achievement of certain milestones. The following assumptions were
used to value the remaining unvested warrants on March&amp;#xA0;7, 2011
at the date the consultant effectively became an employee of the
Company: an expected life of 4.28 years, volatility of 135%, risk
free interest rate of 1.705% and zero dividends. Pursuant to an
employment agreement entered into in May 2011 with the consultant,
all remaining unvested warrants were immediately vested. The
Company recognized expense of $213,000 and $340,000 related to
these warrants during the three and six months ended June&amp;#xA0;30,
2011, respectively. The Company recognized an expense of $100,000
related to these warrants during the three and six months ended
June&amp;#xA0;30, 2010.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">3000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">-889000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">785000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Commitments and
Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Separation Agreement
&amp;#x2013; Former Chief Executive Officer and Chairman of the Board of
Directors&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In February
2009, the Company entered into a Separation Agreement in connection
with the resignation of David Platt, Ph.D., the Company&amp;#x2019;s
former Chief Executive Officer and Chairman of the Board of
Directors. The Separation Agreement provides that the Company shall
continue to pay Dr.&amp;#xA0;Platt his salary at a monthly rate of
$21,667 for 24 months as well as health and dental benefits. The
Company recognized the full amount of the salary, health insurance
and automobile during the first quarter of 2009. The remaining
liability related to this severance was reflected in accrued
expenses ($293,000) on the condensed consolidated balance sheet at
December&amp;#xA0;31, 2010 and was paid to Dr.&amp;#xA0;Platt on
February&amp;#xA0;12, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Separation
Agreement also provides for the deferral of a $1.0 million
severance payment due to Dr.&amp;#xA0;Platt under his employment
agreement until the occurrence of any of the following milestone
events: (i)&amp;#xA0;the approval by the Food and Drug Administration
for a new drug application (&amp;#x201C;NDA&amp;#x201D;) for any drug
candidate or drug delivery candidate based on the GM-CT-01
technology (whether or not such technology is patented), in which
case Dr.&amp;#xA0;Platt is also entitled to a fully vested 10-year
cashless-exercise stock option to purchase at least 500,000 shares
of common stock at an exercise price not less than the fair market
value of the common stock determined as of the date of grant;
(ii)&amp;#xA0;consummation of a transaction with a pharmaceutical
company expected to result in at least $10.0 million of equity
investment or $50 million of royalty revenue to the Company, in
which case Dr.&amp;#xA0;Platt is also entitled to stock options on the
same terms to purchase at least 300,000 shares of common stock; or
(iii)&amp;#xA0;the renewed listing of our securities on a national
securities exchange. Payment upon the events (i)&amp;#xA0;and
(iii)&amp;#xA0;may be deferred up to nine months, and if the Company
has insufficient cash at the time of any of such events, it may
issue Dr.&amp;#xA0;Platt a secured promissory note for such amount. If
the Company file a voluntary or involuntary petition for
bankruptcy, whether or not a milestone event has occurred, such
event shall trigger our obligation to pay the $1.0 million with the
result that Dr.&amp;#xA0;Platt may assert a claim for such obligation
against the bankruptcy estate. Due to the uncertainties regarding
the achievement of any of the milestones as described, the Company
has not accrued for the $1.0 million severance nor has it
recognized the value of the unissued stock options as of
June&amp;#xA0;30, 2011. When it is deemed probable that one or more of
the milestone events will be achieved, the Company will then
recognize the $1.0 million severance and the expense related to the
issuance of the stock option at that time based on the then current
fair value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:24px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Legal
Proceedings&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company
records accruals for such contingencies to the extent that the
Company concludes that their occurrence is probable and the related
damages are estimable. There has been no material change in the
matters reported in our Annual Report on Form 10-K for the year
ended December&amp;#xA0;31, 2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;From time to
time, the Company is exposed to litigation relating to its
operations. The Company is not currently engaged in any legal
proceedings that are expected, individually or in the aggregate, to
have a material, adverse affect on its financial condition or
results of operations.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PreferredStockTextBlock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Preferred
Stock&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Series B Convertible
Preferred Stock&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Through a series
of closings from February 2009 through May 2010, the Company issued
and sold a total of (i)&amp;#xA0;900,000 shares of Series B-1
convertible preferred stock (&amp;#x201C;Series B-1 redeemable
convertible preferred stock&amp;#x201D; or &amp;#x201C;Series B-1&amp;#x201D;) and
related common stock warrants for 10,800,000 shares of common stock
and (ii)&amp;#xA0;2,100,000 shares of Series B-2 convertible preferred
stock (&amp;#x201C;Series B-2 redeemable convertible preferred
stock&amp;#x201D; or &amp;#x201C;Series B-2&amp;#x201D; and together with the
Series B-1, the &amp;#x201C;Series B&amp;#x201D;) and related warrants for
25,200,000 shares of common stock. During the three and six months
ended June&amp;#xA0;30, 2010, the Company issued 440,000 and 770,000
shares of Series B-2 and related warrants, respectively, for net
proceeds of $833,000 and $1,463,000, respectively. Pursuant to an
agreement with the holder of all shares of Series B, on
January&amp;#xA0;26, 2011, the Company amended and restated the
Certificate of Designation of Preferences, Rights and Limitations
for the Series B-1 Convertible Preferred Stock and Series B-2
Convertible Preferred Stock, as previously amended, to
(i)&amp;#xA0;delete Section&amp;#xA0;5(c) (entitled &amp;#x201C;Mandatory
Conversion&amp;#x201D;) in order to remove the Company&amp;#x2019;s right to
compel conversion of the Series B Preferred Stock to shares of its
Common Stock, (ii)&amp;#xA0;amend the definitions in Section&amp;#xA0;1
(entitled &amp;#x201C;Definitions&amp;#x201D;) of the terms &amp;#x201C;Series B-1
Redemption Date&amp;#x201D; and the &amp;#x201C;Series B-2 Redemption
Date&amp;#x201D; in order to extend such redemption dates to be the
earlier of February&amp;#xA0;12, 2019, or the date of a promissory note
issued to David Platt, Ph.D. pursuant to a separation agreement
between him and the Company, (iii)&amp;#xA0;amend Section&amp;#xA0;3
(entitled &amp;#x201C;Dividends&amp;#x201D;) such that dividends are payable
in cash or shares of Common Stock valued at 100% of the volume
weighted average price of the Common Stock for the 20 consecutive
trading days prior to the dividend payment date on and after
September&amp;#xA0;30, 2011, and (iv)&amp;#xA0;insert new Section&amp;#xA0;5(d)
(entitled &amp;#x201C;Automatic Conversion Upon Transfer&amp;#x201D;) to
require that any request for transfer of shares of Series B
Preferred Stock to another holder shall result in an automatic
conversion to shares of Common Stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:24px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Series C 6% Super
Dividend Convertible Preferred Stock&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
December&amp;#xA0;29, 2010, the Company designated and authorized the
sale and issuance of up to 1,000 shares of Series C Super Dividend
Convertible Preferred Stock (&amp;#x201C;Series C&amp;#x201D;) with a par
value of $0.01 and a stated value equal to $10,000 (the
&amp;#x201C;Stated Value&amp;#x201D;).&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
December&amp;#xA0;30, 2010, the Company sold and issued 212 shares of
Series C at a price of $10,000 per share for gross proceeds of
$2,120,000. The Company incurred $47,000 of cash transaction costs
resulting in net cash proceeds of $2,073,000. In addition, the
Company issued 3,000 warrants exercisable at $1.20 to a placement
agent which had a de minimis value.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;During January
2011, the Company sold and issued 13 shares of Series C at a price
of $10,000 per share for gross proceeds of $130,000.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The terms of the
Series C are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Conversion
Rights&lt;/i&gt;. Each holder of Series C may convert all, but not less
than all, of his Series C shares plus accrued and unpaid dividends
into Common Stock at the price of $1.00 per share of Common Stock
(&amp;#x201C;Conversion Price&amp;#x201D;), such that 10,000 shares of Common
Stock will be issued per each converted share of Series C (accrued
and unpaid dividends will be issued as additional
shares).&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Subject to the
continuing obligation to pay post conversion dividends, the Company
may convert all, but not less than all, of the Series C (plus all
accrued and unpaid dividends) into Common Stock, at the Conversion
Price, upon such time that the closing price of the Common Stock is
no less than $3.00 per share for 15 consecutive trading
days.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%;padding-bottom:0px;"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Dividends&lt;/i&gt;. Holders of Series C shall be entitled to
receive cumulative non-compounding dividends at the rate per share
of Series C equal to the greater of (i)&amp;#xA0;6%&amp;#xA0;per annum of
the Stated Value (also defined as the &amp;#x201C;Floor&amp;#x201D;) or
(ii)&amp;#xA0;2.5% of net sales until the total dividends paid is equal
to the initial investment and 1.25% of net sales thereafter. The
maximum amount each Series C shareholder will receive in dividend
payments is equal to $100,000 (the &amp;#x201C;Maximum
Payout&amp;#x201D;).&amp;#xA0;For purposes of this dividend calculation, net
sales shall mean gross revenues actually received by the Company,
from the sale or licensing of the product DAVANAT&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;sup style="vertical-align:baseline; position:relative; bottom:.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;,
less chargebacks, returns, expenses attributable to product
recalls, duties, customs, sales tax, freight, insurance, shipping
expenses, allowances and other customary deductions.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The dividend
shall be payable in arrears semi annually on March&amp;#xA0;31 and
September&amp;#xA0;30, beginning with the first such date after the
original issue date; provided, however, that all dividends and all
other distributions shall cease, and no further dividends or other
distributions shall be paid, in respect of each share of Series C
from and after such time that the Maximum Payout has been paid in
respect of such share of Series C. Such dividends shall be payable
at the Company&amp;#x2019;s option either in cash or in duly authorized,
fully paid and non-assessable shares of Common Stock valued at the
higher of (i)&amp;#xA0;$0.50 per share or (ii)&amp;#xA0;the average of the
Common Stock trading price for the ten (10)&amp;#xA0;consecutive
trading days ending on the trading day that is immediately prior to
the dividend payment date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Series C Post
Conversion Dividend Right&lt;/i&gt;. In the event that any share of
Series C is converted into Common Stock before the Maximum Payout
is paid in respect of such converted share of Series C, then the
holder shall have the right to continue to receive dividends in
respect of such converted share of Series C equal to the remaining
payout (the &amp;#x201C;Series C Preferred Stock Post Conversion
Dividend Right&amp;#x201D;) which shall be equal to the Maximum Payout
less the cumulative dividends received through the conversion date.
One share of Series C Preferred Stock Post Conversion Dividend
Right shall be issued for each such converted share of Series C.
The holder of each Series C Preferred Stock Post Conversion
Dividend Right shall receive the remaining payout on an equal basis
and in conjunction with the then outstanding shares of Series C and
all the other then outstanding Series C Post Conversion Dividend
Rights, in the same manner and subject to the same terms and
conditions as applicable to the payment of dividends on each share
of Series C, except that for purposes of calculating the dividend
the Floor shall not apply. The Series C Preferred Stock Post
Conversion Dividend Right shall have no stated value, liquidation
preference or right to any dividends or distributions other than
the remaining payout. The Series C Preferred Stock Post Conversion
Right is subject to redemption in the same manner as outstanding
Series C shares.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;At the date of
issuance, the Series C have an embedded dividend right to continue
to receive dividend payments after conversion to common stock (the
Series C Post Conversion Dividend Right) which requires
bifurcation. The value of this post conversion dividend right on
the date of issuance was determined to be de minimis due to the
payment of a dividend stream other than the 6% dividend and
conversion of Series C prior to the Company achieving sales of
GM-CT-01 was deemed improbable at that time. Upon a conversion of
the Series C, the Company will be required to record a liability
and the related expense during the period of conversion. The
Company will continue to evaluate and assess the Series C Post
Conversion Dividend Right for each reporting period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Liquidation
Rights&lt;/i&gt;. In the event of any liquidation, dissolution or winding
up of the Company, either voluntarily or involuntarily, the holders
of Series C will receive $10,000 per share plus accrued and unpaid
dividends, payable prior and in preference to any distributions to
the holders of Common Stock but after and subordinate to the Series
A 12% Convertible Preferred Stock (&amp;#x201C;Series A&amp;#x201D;), Series
B-1 and Series B-2, subject to the Maximum Payout.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Redemption&lt;/i&gt;. Upon a sale of the Company, the Company
shall redeem all of the then outstanding shares of Series C and
Series C Preferred Stock Post Conversion Rights within thirty
(30)&amp;#xA0;days after the transaction constituting the sale of the
Company is closed and such closing is fully funded. The price to
redeem a share of Series C and each redeemed Series C Preferred
Stock Post Conversion Redemption Right shall be equal to
(i)&amp;#xA0;(A)&amp;#xA0;the applicable return on investment
(&amp;#x201C;ROI&amp;#x201D;) percentage, multiplied by (B)&amp;#xA0;$10,000,
minus (ii)&amp;#xA0;the cumulative dividends received through the
redemption date. The redemption price shall be payable at our
option either in cash or in shares of common stock valued at the
higher of (i)&amp;#xA0;$0.50 per share or (ii)&amp;#xA0;the average market
price for the ten consecutive trading days ending immediately prior
to the date of redemption. The ROI Percentage shall mean the
percentage that applies as of the redemption date, as
follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px;page-break-before:always"&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="95%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"&gt;
&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="11%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td width="87%"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;
&lt;!-- Begin Table Body --&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;u&gt;ROI&amp;#xA0;Percentage&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;200%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;before the second anniversary of the date of
issuance;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;250%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;on or after the second anniversary of the date of issuance, but
before the third anniversary of the date of issuance;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;300%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;on or after the third anniversary of the date of issuance, but
before the fourth anniversary of the date of issuance;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;350%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;on or after the fourth anniversary of the date of issuance, but
before the fifth anniversary of the date of issuance;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;400%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;on or after the fifth anniversary of the date of issuance, but
before the sixth anniversary of the date of issuance;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;450%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;on or after the sixth anniversary of the date of issuance, but
before the seventh anniversary of the date of issuance;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;500%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;on or after the seventh anniversary of the date of issuance,
but before the eighth anniversary of the date of issuance;
and&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;550%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;on or after the eighth anniversary of the date of issuance, but
before the ninth anniversary of the date of issuance.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Body --&gt;&lt;/table&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Due to the
redemption feature, the Company has presented the Series C outside
of permanent equity, in the mezzanine of the consolidated balance
sheet at June&amp;#xA0;30, 2011 and December&amp;#xA0;31, 2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Voting
Rights&lt;/i&gt;. The Series C shares have no voting rights.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:PreferredStockTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">-48260000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">2713000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Loss Per
Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Basic loss per
share is based on the weighted-average number of common shares
outstanding during each period. Diluted loss per share is based on
basic shares as determined above plus the incremental shares that
would be issued upon the assumed exercise of in-the-money stock
options and warrants using the treasury stock method. The
computation of diluted net loss per share does not assume the
issuance of common shares that have an anti-dilutive effect on net
loss per share. For the three and six-month periods ended
June&amp;#xA0;30, 2011 and 2010, all stock options, warrants and
potential shares related to conversion of the Series A, the Series
B and the Series C were excluded from the computation of diluted
net loss per share. Dilutive shares which could exist pursuant to
the exercise of outstanding stock instruments and which were not
included in the calculation because their affect would have been
anti-dilutive are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE"&gt;&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="67%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;
&lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;June&amp;#xA0;30,&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;2011&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;(Shares)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;
&lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;June&amp;#xA0;30,&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;2010&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;(Shares)&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;
&lt;!-- Begin Table Body --&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="5" valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Warrants to purchase shares
of common stock&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;42,789,400&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;55,178,481&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Options to purchase shares
of common stock&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;19,313,492&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;11,877,250&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Restricted shares subject to
vesting&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;125,000&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;725,000&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Shares of common stock
issuable upon conversion of preferred stock&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;15,812,500&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;13,617,500&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="5" valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;78,040,392&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;81,398,231&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="5" valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">171000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Agreement with PROCAPS
S.A. and Research Grants&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Agreement with PROCAPS
S.A.&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%;padding-bottom:0px;"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;On
March&amp;#xA0;25, 2010, the Company granted PROCAPS S.A.
(&amp;#x201C;PROCAPS&amp;#x201D;) exclusive rights to market and sell
GM-CT-01 (formerly DAVANAT&lt;font style="font-family:Times New Roman" size="1"&gt;&lt;sup style="vertical-align:baseline; position:relative; bottom:.8ex"&gt;&amp;#xAE;&lt;/sup&gt;&lt;/font&gt;)
to treat cancer in Colombia, South America. PROCAPS is an
international, privately held pharmaceutical company based in
Barranquilla, Colombia. Under terms of the agreement, PROCAPS is
responsible for obtaining regulatory and pricing approval in
Colombia. PROCAPS is responsible for the vial filling, packaging,
marketing and distribution of GM-CT-01 in the region.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In October 2010,
the Company received a payment of $200,000 and shipped GM-CT-01 to
PROCAPS to be used by PROCAPS to qualify its vial filling process
and to replicate the Company&amp;#x2019;s stability study. Should the
Company gain approval in Colombia, PROCAPS may then obtain the
marketing authorization in other countries in Latin America. The
Company recorded the $200,000 payment from PROCAPS as deferred
revenue on the condensed consolidated balance sheets as of
June&amp;#xA0;30, 2011 and December&amp;#xA0;31, 2010 and will recognize
the revenue when the remaining deliverables of the collaboration
agreement have been completed.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Qualifying Therapeutic
Discovery Project&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In October 2010,
the Company was awarded $489,000 total in two federal grants under
the Qualifying Therapeutic Discovery Project (&amp;#x201C;QTDP&amp;#x201D;)
Program for its GM-CT-01 anti-cancer compound and for its
GR/GM-Series of anti-fibrotic, cirrhosis compounds for work
performed during 2010 and 2009. The Company recognized this grant
in other income in the statement of operations for the year ended
December&amp;#xA0;31, 2010. The Company received $255,000 of the grant
in 2010 and the remaining $234,000 was received in 2011 and was
included in grants receivable on the consolidated balance sheet at
December&amp;#xA0;31, 2010.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">8376000</us-gaap:ShareBasedCompensation>
  <us-gaap:BasisOfAccounting contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Basis of
Presentation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Galectin
Therapeutics, Inc. (the &amp;#x201C;Company&amp;#x201D;) is a
development-stage company that is applying its leadership in
galectin science and drug development to create new therapies for
fibrotic disease and cancer. These candidates are based on the
Company&amp;#x2019;s targeting of galectin proteins which are key
mediators of biologic and pathologic function. These compounds also
may have application for drugs to treat other diseases and chronic
health conditions. The Company was founded in July 2000, was
incorporated in the State of Nevada in January 2001 under the name
&amp;#x201C;Pro-Pharmaceuticals, Inc.,&amp;#x201D; and changed its name to
&amp;#x201C;Galectin Therapeutics, Inc.&amp;#x201D; on May&amp;#xA0;26,
2011.&amp;#xA0;The condensed consolidated financial statements include
the accounts of the Company and its wholly-owned subsidiaries,
Pro-Pharmaceuticals Securities Corp., which was incorporated in
Delaware on December&amp;#xA0;23, 2003, and Medi-Pharmaceuticals, Inc.,
which was incorporated in Nevada on August&amp;#xA0;17, 2010. All
intercompany transactions have been eliminated.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The unaudited
condensed consolidated financial statements as reported in this
Quarterly Report on Form 10-Q reflect all adjustments which are, in
the opinion of management, necessary to present fairly the
financial position of the Company as of June&amp;#xA0;30, 2011 and the
results of its operations for the three and six-months ended
June&amp;#xA0;30, 2011 and 2010 and the cumulative period from
inception (July 10, 2000) through June&amp;#xA0;30, 2011 and its cash
flows for the six months ended June&amp;#xA0;30, 2011 and 2010, and for
the cumulative period from inception (July 10, 2000) to
June&amp;#xA0;30, 2011. All adjustments made to the interim financial
statements include all those of a normal and recurring nature. The
Company considers events or transactions that occur after the
balance sheet date but before the financial statements are issued
to provide additional evidence relative to certain estimates or to
identify matters that require additional disclosure. Subsequent
events have been evaluated through the date these financial
statements are available to be issued. The results for interim
periods are not necessarily indicative of results which may be
expected for any other interim period or for the full
year.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The unaudited
condensed consolidated financial statements of the Company should
be read in conjunction with its Annual Report on Form 10-K for the
year ended December&amp;#xA0;31, 2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;As shown in the
unaudited condensed consolidated financial statements, the Company
incurred cumulative net losses applicable to common stockholders of
approximately $63.3 million for the cumulative period from
inception (July 10, 2000) through June&amp;#xA0;30, 2011. The
Company&amp;#x2019;s net losses have resulted principally from costs
associated with (i)&amp;#xA0;research and development expenses,
including clinical trial costs, (ii)&amp;#xA0;general and
administrative activities and (iii)&amp;#xA0;the Company&amp;#x2019;s
financing transactions including interest and the costs related to
fair value accounting for the Company&amp;#x2019;s convertible debt
instrument and warrant liabilities. As a result of planned
expenditures for future research, discovery, development and
commercialization activities and potential legal cost to protect
its intellectual property, the Company expects to incur additional
losses and use additional cash in its operations for the
foreseeable future. From inception (July 10, 2000) through
June&amp;#xA0;30, 2011, the Company has raised a net total of
approximately $57.1 million in capital through sale and issuance of
common stock, common stock warrants, convertible preferred stock,
redeemable convertible preferred stock, convertible debt securities
in public and private offerings and the exercise of common stock
options and warrants. From inception (July 10, 2000) through
June&amp;#xA0;30, 2011, the Company has used approximately $48.3
million of cash in its operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;At June&amp;#xA0;30,
2011, the Company had $7,984,000 of unrestricted cash and cash
equivalents available to fund future operations. The Company
believes that with the funds on hand at June&amp;#xA0;30, 2011, there
is sufficient cash to fund operations through 2012. The Company is
actively seeking to raise additional capital. If the Company is
unsuccessful in raising additional capital before the end of 2012,
the Company may be required to cease operations or seek bankruptcy
protection.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company is
subject to a number of risks similar to those of other
development-stage companies, including dependence on key
individuals, uncertainty of product development and generation of
revenues, dependence on outside sources of capital, risks
associated with clinical trials of products, dependence on
third-party collaborators for research operations, need for
regulatory approval of products, risks associated with protection
of intellectual property, and competition with larger,
better-capitalized companies. Successful completion of the
Company&amp;#x2019;s development program and, ultimately, the attainment
of profitable operations is dependent upon future events, including
obtaining adequate financing to fulfill its development activities
and achieving a level of revenues adequate to support the
Company&amp;#x2019;s cost structure. There are no assurances that the
Company will be able to obtain additional financing on favorable
terms, or at all, or successfully market its products.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:BasisOfAccounting>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">774000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:InterestExpense contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">4451000</us-gaap:InterestExpense>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">64000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:PaymentsToAcquireProductiveAssets contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">404000</us-gaap:PaymentsToAcquireProductiveAssets>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Subsequent
Events&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="margin-top:24px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company has
evaluated all events or transactions that occurred through the date
on which the financial statements were issued, noting the
following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In July 2011, a
shareholder converted 5 shares of Series C to 50,000 shares of
common stock and was issued a Series C Post Conversion Dividend
Right under which the Company will continue to pay dividends until
$100,000 for each share of Series C has been paid.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In July 2011,
the Company entered into an agreement to amend its operating lease
for office space to extend the lease for a period of one year,
expiring on September&amp;#xA0;30, 2012, at a base rent of $235,000 for
the term.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In July 2011,
the Company entered into an operating lease for an apartment for
Company executive use for a one-year term, ending July 2012, at a
rate of $41,000 for the term.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">3700000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">-56921000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">2421000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">21566000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">12243000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">-63334000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">351000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">421000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">542000</us-gaap:DepreciationAndAmortization>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">1641000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">-59342000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">491000</us-gaap:OtherNonoperatingIncome>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">10621000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">7984000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">68000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Fair Value of Financial
Instruments&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="margin-top:6px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;In general, fair
values determined by Level&amp;#xA0;1 inputs utilize quoted prices
(unadjusted) in active markets for identical assets or liabilities.
Fair values determined by Level&amp;#xA0;2 inputs utilize data points
that are observable, such as quoted prices, interest rates and
yield curves. Fair values determined by Level&amp;#xA0;3 inputs utilize
unobservable data points for the asset or liability. The
Company&amp;#x2019;s financial liabilities were classified as
Level&amp;#xA0;2. These Level 2 liabilities consisted of warrant
liabilities at December&amp;#xA0;31, 2010 and have been valued using
the Black-Scholes pricing model. The Company did not have any
warrant liabilities at June&amp;#xA0;30, 2011.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The Company uses
the Black-Scholes pricing model to calculate fair value of its
warrant liabilities. Key assumptions used to apply these models are
as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"&gt;
&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="71%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="21%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;br /&gt;

&lt;font style="font-family:Times New Roman" size="2"&gt;2010&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;
&lt;!-- Begin Table Body --&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Risk free interest
rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0.19%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Expected life&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0.62&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Expected volatility of
common share price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;70%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Common share
price&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$0.90&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Body --&gt;&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;Below is a summary of our fair value measurements
at December&amp;#xA0;31, 2010:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"&gt;
&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="64%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;
&lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Value&amp;#xA0;at&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Period&amp;#xA0;End&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Quoted&amp;#xA0;prices&amp;#xA0;in&lt;br /&gt;
active markets&lt;br /&gt;
(Level&amp;#xA0;1)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Significant&amp;#xA0;other&lt;br /&gt;
observable&amp;#xA0;inputs&lt;br /&gt;
(Level&amp;#xA0;2)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;
&lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Significant&lt;br /&gt;
unobservable&amp;#xA0;inputs&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;(Level&amp;#xA0;3)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="14" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;
&lt;!-- Begin Table Body --&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;December&amp;#xA0;31,
2010:&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Warrant
liabilities&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;861&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;861&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Body --&gt;&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The
Company&amp;#x2019;s financial instruments consist of cash equivalents,
accounts payable and accrued expenses. The estimated fair value of
these financial instruments approximates their carrying value due
to their short-term nature.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:InterestPaid contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">114000</us-gaap:InterestPaid>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Accrued
Expenses&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Accrued expenses
consist of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"&gt;
&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="92%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;June&amp;#xA0;30,&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;br /&gt;

2011&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;December&amp;#xA0;31,&lt;br /&gt;
2010&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;
&lt;!-- Begin Table Body --&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Legal and accounting
fees&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;88&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;94&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Accrued
compensation&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;55&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;87&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Severance agreement (Note
9)&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;-&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;293&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;233&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;63&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;376&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;537&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">59342000</us-gaap:OperatingExpenses>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0">&lt;div&gt;
&lt;table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
&lt;tr&gt;
&lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td align="left" valign="top"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;b&gt;Stock-Based
Compensation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;!-- xbrl,body --&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Following is the
stock-based compensation expense related to common stock options,
restricted common stock and common stock warrants:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="100%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"&gt;
&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="88%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;
&lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;u&gt;Three
Months&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;u&gt;Ended&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;u&gt;June&amp;#xA0;30,&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="6" align="center"&gt;
&lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;u&gt;Six
Months&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;u&gt;Ended&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:1px" align="center"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;u&gt;June&amp;#xA0;30,&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2010&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2010&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;
&lt;!-- Begin Table Body --&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="13" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(in thousands)&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Research and
development&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;614&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;3&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;1,138&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;82&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;General and
administrative&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;714&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;571&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;901&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,089&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="13" valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:2.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Total stock-based
compensation expense&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,328&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;574&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2,039&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1,171&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="13" valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Body --&gt;&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Included in
stock-based compensation for the six months ended June&amp;#xA0;30,
2010 was $70,000 of research and development expenses and $295,000
of general and administrative expenses which were accrued for as
bonuses as of December&amp;#xA0;31, 2009 and which were paid with the
issuance of options in 2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Common Stock
Options&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The following
table summarizes the stock option activity in the Company&amp;#x2019;s
equity incentive plans from December&amp;#xA0;31, 2010 through
June&amp;#xA0;30, 2011:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"&gt;
&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="92%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Shares&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
Exercise Price&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;
&lt;!-- Begin Table Body --&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Outstanding,
December&amp;#xA0;31, 2010&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;11,794,250&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&amp;#xA0;&amp;#xA0;1.07&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;9,841,242&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1.17&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Exercised&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(913,000)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0.20&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Options
forfeited/cancelled&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(1,409,000)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1.08&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Outstanding, June&amp;#xA0;30,
2011&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;19,313,492&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;$&amp;#xA0;&amp;#xA0;1.16&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Body --&gt;&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;As of
June&amp;#xA0;30, 2011, there was $8,222,000 of unrecognized
compensation related to 8,469,422 unvested options, which is
expected to be recognized over a weighted&amp;#x2013;average period of
approximately 3.1 years. The weighted-average grant date fair value
for options granted during the three and six months ended
June&amp;#xA0;30, 2011 was $1.04 and $1.02, respectively. The
weighted-average grant date fair value for options granted during
the six months ended June&amp;#xA0;30, 2010 was $0.26; there were no
options granted during the three months ended June&amp;#xA0;30,
2010.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="margin-top:0px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;Of the options
granted during the six months ended June&amp;#xA0;30, 2011, 1,000,000
vest only upon the achievement of certain market conditions
(500,000 and 500,000 upon the Company achieving a market
capitalization of $5 billion and $10 billion, respectively). These
market condition stock option awards were valued at $1,006,000
using a Monte Carlo model and will be recognized over a weighted
average period of 5.5 years. Assumptions used to value these
options included the following: annualized volatility of 110%,
annualized drift/risk-free interest rate of 3.5% and a forecast
horizon life of 10 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The fair value
of the options granted, other than as noted, is determined using
the Black-Scholes option-pricing model. The following weighted
average assumptions were used:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="86%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"&gt;
&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="88%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="3" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Six Months&amp;#xA0;Ended&lt;br /&gt;
June 30,&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Cumulative&lt;br /&gt;
Period&amp;#xA0;from&lt;br /&gt;
Inception&lt;br /&gt;
(July&amp;#xA0;10,&amp;#xA0;2000)&amp;#xA0;to&lt;br /&gt;
June 30,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2011&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;2010&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2011&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;
&lt;!-- Begin Table Body --&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Risk-free interest
rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;1.91%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2.38%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;2.23%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Expected life of the
options&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5.1&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;5.0&amp;#xA0;years&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Expected volatility of the
underlying stock&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;121%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;126%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;116%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Expected dividend
rate&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0%&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="center"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;0%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Body --&gt;&lt;/table&gt;
&lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&lt;i&gt;Restricted
Stock.&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;During the year
ended December&amp;#xA0;31, 2009, the Company granted 2,500,000 shares
of restricted common stock to members of its Board of Directors. Of
the 2,500,000 shares, 2,343,750 were vested as of December&amp;#xA0;31,
2010 and the remaining 156,250 vested during the six months ended
June&amp;#xA0;30, 2011. The restricted shares were valued at $450,000
($0.18 per share) at the date of grant, which was recognized over
the vesting period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;During the three
and six months ended June&amp;#xA0;30, 2011, the Company issued 125,000
shares of restricted common stock to a consultant. These shares are
restricted until November&amp;#xA0;15, 2011 and any unvested shares are
subject to forfeiture upon termination and would revert back to the
Company. At June&amp;#xA0;30, 2011 there were 125,000 restricted shares
remaining. The restricted shares were valued at $152,000 ($1.22 per
share) at June&amp;#xA0;30, 2011 and will be adjusted for unvested
shares and will be recognized over the vesting period. During the
three and six months ended June&amp;#xA0;30, 2011, the Company
recognized $45,000 and $81,000 of stock-based compensation,
respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12px;margin-bottom:0px; text-indent:2%"&gt;
&lt;font style="font-family:Times New Roman" size="2"&gt;The following
table summarizes restricted stock option activity from
December&amp;#xA0;31, 2010 through June&amp;#xA0;30, 2011:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center"&gt;
&lt;!-- Begin Table Head --&gt;
&lt;tr&gt;
&lt;td width="79%"&gt;&lt;/td&gt;
&lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Shares&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;!-- End Table Head --&gt;
&lt;!-- Begin Table Body --&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Restricted, December 31,
2010&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;156,250&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Granted&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;125,000&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCEEFF"&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Vested&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;(156,250)&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:1px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;Restricted, June 30,
2011&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;125,000&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:Times New Roman" size="2"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td valign="bottom"&gt;&lt;/td&gt;
&lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom"&gt;
&lt;p style="border-top:3px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">37776000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">57133000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:PaidInKindInterest contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">4279000</us-gaap:PaidInKindInterest>
  <galt:SupplementalDividendsOnConvertiblePreferredStock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">2713000</galt:SupplementalDividendsOnConvertiblePreferredStock>
  <galt:ProceedsFromExerciseOfStockOptionsAndOtherStockIssuances contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">10077000</galt:ProceedsFromExerciseOfStockOptionsAndOtherStockIssuances>
  <galt:ChangeInFairValueOfWarrant contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">9022000</galt:ChangeInFairValueOfWarrant>
  <galt:UnrealizedGainLossInDebtInstrumentFairValue contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">3426000</galt:UnrealizedGainLossInDebtInstrumentFairValue>
  <galt:ConversionOfAccruedLiabilitiesToCommonStock contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">303000</galt:ConversionOfAccruedLiabilitiesToCommonStock>
  <galt:IssuanceOfEquityWarrantsInConnectionWithEquityOfferings contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">5037000</galt:IssuanceOfEquityWarrantsInConnectionWithEquityOfferings>
  <galt:CashlessExerciseOfStockOptions contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">98000</galt:CashlessExerciseOfStockOptions>
  <galt:IssuanceOfWarrantsToInduceConversionOfNotesPayable contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0" unitRef="iso4217_USD" decimals="-3">503000</galt:IssuanceOfWarrantsToInduceConversionOfNotesPayable>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0_453257x444581" unitRef="iso4217_USD" decimals="-3">28690000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0_453257x445724" unitRef="iso4217_USD" decimals="-3">1691000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0_453257x449416" unitRef="iso4217_USD" decimals="-3">2203000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0_453257x479231" unitRef="iso4217_USD" decimals="-3">1548000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="eol_PE87402---1110-Q0004_STD_4008_20110630_0_453257x479232" unitRef="iso4217_USD" decimals="-3">3935000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">1000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">227000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">594000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">-1654000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">-304000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">234000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">-2475000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">-1350000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">1350000</us-gaap:OperatingExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">1116000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
  <galt:ChangeInFairValueOfWarrant contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">-305000</galt:ChangeInFairValueOfWarrant>
  <galt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_91_20100630_0" unitRef="shares" decimals="-3">53911000</galt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">4000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">750000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">57000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">-3127000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">-136000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">1291000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">-3934000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">-2991000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">2991000</us-gaap:OperatingExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">1700000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
  <galt:ChangeInFairValueOfWarrant contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">-140000</galt:ChangeInFairValueOfWarrant>
  <galt:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE87402---1110-Q0004_STD_91_20110630_0" unitRef="shares" decimals="-3">69540000</galt:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <context id="eol_PE87402---1110-Q0004_STD_91_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_91_20100630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2010-04-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_4008_20110630_0_453257x479232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2000-07-10</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_4008_20110630_0_453257x479231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB1PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2000-07-10</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_4008_20110630_0_453257x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2000-07-10</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_4008_20110630_0_453257x445724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2000-07-10</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_4008_20110630_0_453257x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2000-07-10</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_4008_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2000-07-10</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_453257x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_453257x445724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x479232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:SeriesB2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x479231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:SeriesB1PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726_453257x479232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726_453257x479231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB1PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726_453257x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726_453257x445724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698_453257x479232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698_453257x479231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB1PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698_453257x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698_453257x445724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x445724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581_453257x479232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581_453257x479231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB1PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581_453257x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581_453257x445724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20100630_0_453257x479232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_181_20100630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x479232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x479231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB1PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_453257x445724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x479232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:SeriesB2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x479231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:SeriesB1PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x445724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x479231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesB1PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_453257x445724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x479232">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:SeriesB2PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x479231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:SeriesB1PreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x478726">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">galt:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStageMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x449416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x445724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20100630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2010-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1110-Q0004_STD_0_20110810_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2011-08-10</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
</xbrl>